INFORMATION DISCLOSURE STATEMENT

FORM 1449*

Application Number:

10/692,299

Docket Number:

11669.139USC1

	IN AN APPLICATION (Use several sheets if necessary)			Applicant: FERRARA ET AL.				
FFB 2 1 2006				Filing Date: 10/22/2	003 Grou	Art Unit: 1644		
FER 2 1 2006								
THE PARTY OF	y		J.S. PATENT DOCU	MENTS	 	······································		
EXAMINER	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	BCLASS FILING DATE		
INITIAL	2000277.710.	J		02/105	JODELAGS		IF APPROPRIATE	
					·			
	<u> </u>	<u> </u>						
		ļ						
<u></u>		·						
		FOR	EIGN PATENT DO	CUMENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	TRANSLATION	
						YES	NO	
Pr.M	0 834 563 A2	04/08/1998	EP					
	1 033 401 A2	09/06/2000	EP					
	0 607 054 B1	11/20/2002	EP		<u> </u>		<u></u>	
	WO 97/07198	02/27/1997	РСТ					
	WO 98/39448	09/11/1998	PCT		\			
	WO 98/42741	10/01/1998	РСТ					
	WO 99/46375	09/16/1999	РСТ			Abstract		
	WO 99/53040	10/21/1999	PCT			Abstract		
	WO 99/63083	12/09/1999	PCT			Abstract		
/	WO 00/08145	02/17/2000	PCT					
	WO 01/57190 A2	08/09/2001	PCT		1	\backslash		

EXAMINER DATE CONSIDERED 3/29/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 11669.139USC1	Application Number: 10/692,299		
IN AN APPLICATION	Applicant: FERRARA ET AL.			
(Use several sheets if necessary)	Filing Date: 10/22/2003	Group Art Unit: 1644		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
PM	NCBI, Accession Number: AF131820; Direct Submission, Submitted: February 26, 1999, Mei, G. et al.
1	NCBI, Accession Number: AA865629; National Cancer Institute, 1997, Strausberg, Robert
	NCBI, Accession Number: AA150370; Genome Research, 1996, Hillier, L. et al.
	NCBI, Accession Number: AA843667, National Cancer Institute, 1997, Strausberg, Robert
	Brandon, C., "Improved Immunocytochemical Straining Through the Use of Fab Fragments of Primary Antibody, Fab-specific Second Antibody, and Fab-Horseradish Peroxidase," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 33, No. 7, pp. 715-719 (1985)
	Klein, R. et al., "Selection for Genes Encoding Secreted Proteins and Receptors," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 7108-7113 (July 1996)
	Schnabel, M. et al., "Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture," <i>Osteoarthritis and Cartilage</i> , Vol. 10, pp. 62-70 (2002)
:	Tashiro, K. et al., "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins," <i>Science</i> , Vol. 261, pp. 600-603 (July 30, 1993)
	Wallin, E. et al., "Properties of N-terminal tails in G-protein coupled receptors: a statistical study," <i>Protein Engineering</i> , Vol. 8, No. 7, pp. 693-698 (1995)
,	Yokoyama-Kobayashi, M. et al., "A signal sequence detection system using secreted protease activity as an indicator," <i>Gene</i> , Vol. 163, pp. 193-196 (1995)
$\sqrt{}$	Zhang, Y. et al., "Versican Modulates Embryonic Chondrocyte Morphology via the Epidermal Growth Factor-like Motifs in G3," Experimental Cell Research, Vol. 263, pp. 33-42 (2001)

23552
PATENT TRADEMARK OFFICE

					,	_
EXAMINER	181 N.	1	DATE CONSIDERED	3/28	106	
	6 7	71				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.